An interventional study of Individual Exercise and Group Exercise in Multiple Myeloma, sponsored by Medical University of Vienna. Suspended at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Multiple Myeloma with a site in Austria — 10 open to participants now, 26 under way, 21 of them phase 3. Multiple Myeloma · Austria.
Among the 92 studies in Multiple Myeloma with a site in Austria, this one is the 70th largest by planned enrollment of the 77 interventional ones that give a count, is the only one that started in 2027, is the only one with no phase, and was the 61st registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →10 of the 92 studies in Multiple Myeloma with a site in Austria are open now. Recruiting first, the newest first:
Takeda · Sites in Austria, United States, Australia and 14 more countries
Ages 18+
European Myeloma Network B.V. · Sites in Austria, Australia, Croatia and 15 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Austria, United States, Argentina and 28 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria, Germany
Ages 18+
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 55
First in 1999; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is close to the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 452 across the 77 interventional studies, 420 across the 14 observational. Of the 60 that completed or were terminated, 34 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 92 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 2 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
4 of the studies in Multiple Myeloma with a site in Austria that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
Add all 4 to your calendar (.ics) → With an account.
Among the 92 studies in Multiple Myeloma with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple myeloma is the second most common haematological cancer with a cancer incidence of around 500 new cases in Austria per year . Novel treatment methods have significantly increased the cancer-specific survival rate in patients with multiple myeloma. For Austria, this means that 5- and 10-year survival rates rose from 32.1 to 46.4% and from 19.0 to 25.6% from the end of the 1980s to the end of the 2000s.
Longer survival is associated with the need to maintain independence and quality of life in the longer term. In this context, regular physical training has seen a significant increase in the importance of cancer in recent years.The guidelines of the American College of Sports Medicine still contain very general training recommendations for cancer patients. Either 150 minutes of moderate or 75 minutes of intensive endurance training per week are recommended, supplemented by at least two units of strengthening training and stretching exercises for the large muscle groups.
In a recent cross-sectional and pilot study with multiple myeloma patients that was carried out at the Clinic for Physical Medicine, Rehabilitation and Occupational Medicine at the Medical University of Vienna (EK 1725/2018), it was on the one hand identified that there was a discrepancy between these patients on the one hand has given actual and perceived risk of falling, and on the other hand it is concluded that training recommendations should be carried out separately in group and individual training according to the actual risk of falling and fracture.
The present project is the follow-up to this cross-sectional investigation. The aim is to examine the feasibility and effects of a structured, physical training program carried out over a period of 12 weeks on physical performance, quality of life, body composition and the risk of falling. The effects of patients with increased risk in individual training sessions are compared to those of lower risk patients in group training sessions. Furthermore, the study patients will be able to bring training partners with them to their own training units if available and for their own security. They are evaluated separately according to qualitative criteria.
The aim of this study is to investigate the feasibility and effectiveness of individualized training support for multiple myeloma patient populations divided into high and low risk according to their fall and fracture risk. The primary hypothesis is that multiple myeloma patients who meet the criteria for a high risk of falling and / or fracture can achieve equivalent adherence rates and training effects through individually compiled individual training, such as multiple myeloma patients with low risk of falling who conduct group training.
The adherence rates are recorded via attendance lists for training and video conferences as well as a training diary for independent training. To record the training effects, physical performance and functionality are measured and the quality of life, sexuality, depression, fatigue, sleep quality, work ability and risk of falling are assessed using standardized, validated questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
Other: Individual Exercise
Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
Other: Group Exercise
Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
Feasibility (Adherence)
We hypothesize that the adherence of "High Risk Patients" to a personal, individualized exercise intervention is equal to that of "Low Risk Patients" performing group exercise.
Time frame: Adherence rates through 12 weeks of exercise intervention program
VO2max
Maximum oxygen consumption in a cardiopulmonary exercise testing
Time frame: Baseline + 12 weeks
Handgrip Strength (HGS)
Handgrip Dynamometer (JAMAR)
Time frame: Baseline + 12 weeks
Six Minute Walk Test (6MWT)
Distance covered when walking as fast as possible in six minutes
Time frame: Baseline + 12 weeks
Tinetti-Test/Performance Oriented Mobility Assessment (POMA)
Risk of Fall Assessment
Time frame: Baseline + 12 weeks
Timed up and Go Test (TUG)
Risk of Fall Assessment
Time frame: Baseline + 12 weeks
Bioimpedance Analysis (BiA)
Body Composition measurement measured with Nutribox (BiA)
Time frame: Baseline + 12 weeks
Five Repetitions Sit-to-Stand Test (5STS)
Test for Lower Extremity Strength (time needed to stand up and sit down on a chair 5 times)
Time frame: Baseline + 12 weeks
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Basic Module (EORTC QLQ-C30)
Cancer specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Baseline + 12 weeks
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma Module (EORTC QLQ-MY20)
Multiple myeloma specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Baseline + 12 weeks
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Fatigue Module (EORTC QLQ-FA12)
Cancer related fatigue specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Baseline + 12 weeks
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Sexual Health Quality Module (EORTC QLQ-SHQ22)
Cancer related sexual health specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Baseline + 12 weeks
International Physical Activity Questionnaire (IPAQ)
Physical Activity (Questionnaire); Patients are asked about the frequency and volume of at least 10 minutes long episodes of vigorous and moderate physical activity during their last 7 days. Higher values indicate higher levels of physical activity.
Time frame: Baseline + 12 weeks
Hospital Anxiety and Depression Scale (HADS)
Anxiety and Depression (Questionnaire); Score range from 0-21; lower scores indicating lower levels anxiety and depression
Time frame: Baseline + 12 weeks
Work Ability Index (WAI)
Work Ability (Questionnaire); Score range 1-10; higher scores indicating higher work ability
Time frame: Baseline + 12 weeks
Pittsburgh Sleep Quality Index (PSQI)
Sleep Quality (Questionnaire); score range from 0 to 21; lower scores indicating healthier sleep quality
Time frame: Baseline + 12 weeks
Falls Efficacy Scale (FES)
Fall Risk Assessment (Questionnaire); score range from 16 to 64; higher values indicate less fall-related self-efficacy (and more concern about falling).
Time frame: Baseline + 12 weeks
Start is estimated for Sep 2027; primary completion for Mar 2028, 6 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Mar 2026 → Sep 2027, primary completion Oct 2026 → Mar 2028 and completion Dec 2026 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →